Before making a voting decision, investors, shareholders and other interested persons of FS Development Corp.
Pardes biosciences registration#
Securities and Exchange Commission (“SEC”) a registration statement on Form S-4, which includes a description of the terms of the business and includes a prospectus with respect to the combined company’s securities to be issued in connection with the business combination and a proxy statement with respect to the shareholder meeting of FS Development Corp. In connection with the Merger Agreement, FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital. On June 29, 2021, Pardes entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with FS Development Corp. For more information, visit Additional Information and Where to Find It Pardes Biosciences is headquartered in Carlsbad CA. This protease is highly similar across all coronaviruses, including known and emerging coronavirus variants. PBI-0451 is designed to inhibit the coronavirus main protease, an essential protein for SARS-CoV-2 replication. The company’s lead product candidate, PBI-0451, is being developed as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.
Pardes leverages structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery. Pardes Biosciences is a clinical-stage biopharmaceutical company committed to solving some of the world’s most pressing public health challenges. The company anticipates reporting clinical data from this Phase 1 study in the fourth quarter of 2021. The company envisions using its platform in the future to build novel drug candidates for the treatment of other diseases with high unmet medical need. To develop this candidate, the company leveraged structure-based drug design and its tunable, reversible covalent chemistry platform. In preclinical studies, PBI-0451 has been shown to inhibit replication of a broad range of coronaviruses including SARS-CoV-2 across multiple in-vitro models, and was well tolerated in clinically enabling toxicity studies.
Pardes biosciences pro#
The highly conserved nature of M pro across multiple coronaviruses, including emerging variants of concern such as Delta and Lambda, supports the potential for PBI-0451 to target both existing and future coronaviruses. PBI-0451 works by inhibiting Viral Main Protease (M pro), a highly conserved key protein in the virus required for its replication, thus blocking the virus’ ability to replicate. 26, 2021 (GLOBE NEWSWIRE) - Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the virus that causes COVID-19.
0 kommentar(er)
